Thrombolytic therapy became the standard of care for acute ischemic stroke after the publication of the Tissue Plasminogen Activator (tPA) for Acute Ischemic Stroke conducted by the National Institute of Neurologic Disorders and Stroke (NINDS tPA trial). The gene discussed is PLAT; the disease is stroke disorder.